Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.21

-0.85%
HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

At a Glance

Live Snapshot
Market Cap$934.78M
EPS-3.7200
P/E Ratio-4.09
Earnings Date08/06/2026

cgem

Total Assets

Last Annual Value

448.37M

3-Year CAGR

-7%

5-Year CAGR

16%

10-Year CAGR

29%

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Competitors Analysis of Total Assets

CGEM · NASDAQ
CompanyTotal Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
448.37M
-2.5%0.5%N/A 
1.11B
-3.9%-0.7%N/A
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
195.80M
49.2%N/AN/A
EHAB logo
Enhabit, Inc.
NYSE:EHAB
1.17B
-6.6%-7.5%N/A
567.75M
20.7%15.6%6.4%
191.05M
-27.3%-14.9%N/A
240.32M
11.5%3.9%N/A
325.63M
-4.9%-4.9%17.1%
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.21, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

Intrinsic Value
Current Price: $15.21